 Daniel Olson
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dengue | 4 | 2024 | 65 | 1.610 |
Why?
| | Zika Virus Infection | 6 | 2024 | 102 | 1.540 |
Why?
| | Guatemala | 18 | 2024 | 311 | 1.480 |
Why?
| | Arbovirus Infections | 2 | 2019 | 18 | 1.230 |
Why?
| | Microcephaly | 4 | 2024 | 57 | 1.200 |
Why?
| | Zika Virus | 5 | 2024 | 77 | 1.190 |
Why?
| | Caliciviridae Infections | 2 | 2018 | 17 | 1.150 |
Why?
| | Dengue Virus | 4 | 2024 | 41 | 1.150 |
Why?
| | Norovirus | 2 | 2018 | 23 | 1.150 |
Why?
| | Viral Vaccines | 2 | 2018 | 93 | 1.120 |
Why?
| | Gastroenteritis | 2 | 2017 | 66 | 1.070 |
Why?
| | Disease Outbreaks | 4 | 2024 | 334 | 0.920 |
Why?
| | Vital Signs | 2 | 2013 | 42 | 0.830 |
Why?
| | Triage | 2 | 2013 | 214 | 0.720 |
Why?
| | Hospitals | 4 | 2016 | 641 | 0.710 |
Why?
| | Stevens-Johnson Syndrome | 2 | 2017 | 38 | 0.690 |
Why?
| | Sentinel Surveillance | 2 | 2017 | 40 | 0.690 |
Why?
| | Global Health | 2 | 2022 | 320 | 0.680 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1272 | 0.660 |
Why?
| | Rural Population | 9 | 2024 | 507 | 0.630 |
Why?
| | Fever | 2 | 2017 | 303 | 0.630 |
Why?
| | Public Health | 2 | 2019 | 496 | 0.550 |
Why?
| | Cell Phone | 1 | 2017 | 70 | 0.540 |
Why?
| | Child Development | 4 | 2022 | 454 | 0.510 |
Why?
| | Health Policy | 1 | 2019 | 361 | 0.490 |
Why?
| | Infant | 18 | 2024 | 9049 | 0.490 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 11 | 0.490 |
Why?
| | Typhoid Fever | 1 | 2015 | 10 | 0.480 |
Why?
| | Health Information Systems | 1 | 2015 | 17 | 0.480 |
Why?
| | Mobile Applications | 1 | 2017 | 159 | 0.480 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2785 | 0.470 |
Why?
| | Meningitis, Bacterial | 1 | 2015 | 52 | 0.470 |
Why?
| | Malaria | 1 | 2015 | 51 | 0.460 |
Why?
| | Paralysis | 1 | 2015 | 72 | 0.460 |
Why?
| | Population Surveillance | 1 | 2017 | 429 | 0.450 |
Why?
| | Child, Preschool | 17 | 2024 | 10514 | 0.440 |
Why?
| | Neuromyelitis Optica | 1 | 2015 | 127 | 0.430 |
Why?
| | Allied Health Personnel | 1 | 2013 | 42 | 0.420 |
Why?
| | Communicable Diseases | 1 | 2015 | 141 | 0.410 |
Why?
| | Developing Countries | 2 | 2019 | 278 | 0.400 |
Why?
| | Growth Disorders | 2 | 2023 | 78 | 0.400 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 771 | 0.390 |
Why?
| | Health Resources | 1 | 2013 | 122 | 0.390 |
Why?
| | Hospital Mortality | 2 | 2013 | 860 | 0.380 |
Why?
| | Hospitalization | 4 | 2015 | 2094 | 0.380 |
Why?
| | Child | 13 | 2022 | 20961 | 0.330 |
Why?
| | Databases, Factual | 1 | 2015 | 1300 | 0.320 |
Why?
| | HIV Infections | 4 | 2015 | 2721 | 0.290 |
Why?
| | Humans | 35 | 2024 | 130305 | 0.290 |
Why?
| | Infant, Newborn | 11 | 2024 | 5741 | 0.290 |
Why?
| | Mycoplasma pneumoniae | 2 | 2017 | 54 | 0.280 |
Why?
| | Serogroup | 2 | 2017 | 30 | 0.270 |
Why?
| | Family Characteristics | 2 | 2018 | 175 | 0.270 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5083 | 0.270 |
Why?
| | Seroepidemiologic Studies | 2 | 2024 | 158 | 0.250 |
Why?
| | Ectoparasitic Infestations | 1 | 2024 | 5 | 0.240 |
Why?
| | Animals, Domestic | 1 | 2024 | 14 | 0.240 |
Why?
| | Acute Disease | 2 | 2017 | 981 | 0.230 |
Why?
| | Culex | 1 | 2023 | 13 | 0.220 |
Why?
| | Malawi | 5 | 2014 | 47 | 0.210 |
Why?
| | Male | 19 | 2024 | 63748 | 0.210 |
Why?
| | Aedes | 1 | 2023 | 57 | 0.210 |
Why?
| | Vomiting | 1 | 2023 | 129 | 0.200 |
Why?
| | Cross Reactions | 1 | 2022 | 130 | 0.200 |
Why?
| | Viruses | 1 | 2023 | 99 | 0.200 |
Why?
| | Adolescent | 7 | 2018 | 20374 | 0.200 |
Why?
| | Cough | 1 | 2023 | 118 | 0.200 |
Why?
| | Neurodevelopmental Disorders | 1 | 2024 | 154 | 0.200 |
Why?
| | Diarrhea | 1 | 2023 | 179 | 0.200 |
Why?
| | Masks | 1 | 2022 | 60 | 0.190 |
Why?
| | Prospective Studies | 8 | 2024 | 7131 | 0.190 |
Why?
| | Yellow fever virus | 1 | 2020 | 3 | 0.180 |
Why?
| | Yellow Fever | 1 | 2020 | 7 | 0.170 |
Why?
| | Neuropsychological Tests | 3 | 2020 | 1004 | 0.170 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 827 | 0.170 |
Why?
| | Health Services Research | 2 | 2013 | 392 | 0.170 |
Why?
| | Female | 18 | 2024 | 68842 | 0.170 |
Why?
| | Language Tests | 1 | 2019 | 33 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2020 | 328 | 0.160 |
Why?
| | Language Development Disorders | 1 | 2019 | 42 | 0.160 |
Why?
| | Americas | 1 | 2019 | 19 | 0.160 |
Why?
| | Motor Skills | 1 | 2020 | 90 | 0.160 |
Why?
| | Arboviruses | 1 | 2018 | 11 | 0.160 |
Why?
| | Dengue Vaccines | 1 | 2018 | 9 | 0.160 |
Why?
| | Sensitivity and Specificity | 4 | 2020 | 1854 | 0.150 |
Why?
| | Antibodies, Viral | 1 | 2022 | 607 | 0.150 |
Why?
| | Cities | 2 | 2016 | 104 | 0.150 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5400 | 0.150 |
Why?
| | Chlamydophila pneumoniae | 1 | 2017 | 12 | 0.140 |
Why?
| | Mycoplasma Infections | 1 | 2017 | 15 | 0.140 |
Why?
| | Chikungunya Fever | 1 | 2018 | 74 | 0.140 |
Why?
| | Referral and Consultation | 2 | 2013 | 736 | 0.140 |
Why?
| | Mouth Mucosa | 1 | 2017 | 89 | 0.140 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2017 | 54 | 0.130 |
Why?
| | Antigens, Viral | 1 | 2017 | 181 | 0.130 |
Why?
| | RNA, Viral | 1 | 2020 | 624 | 0.130 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 18 | 0.130 |
Why?
| | Analgesia, Epidural | 1 | 2016 | 23 | 0.130 |
Why?
| | Neonatal Screening | 1 | 2017 | 164 | 0.130 |
Why?
| | ROC Curve | 2 | 2017 | 507 | 0.130 |
Why?
| | Learning | 1 | 2020 | 391 | 0.120 |
Why?
| | Point-of-Care Systems | 2 | 2014 | 150 | 0.120 |
Why?
| | Data Collection | 1 | 2018 | 654 | 0.120 |
Why?
| | Reference Values | 2 | 2014 | 793 | 0.120 |
Why?
| | Pneumococcal Infections | 1 | 2016 | 111 | 0.120 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 518 | 0.120 |
Why?
| | Streptococcus pneumoniae | 1 | 2016 | 158 | 0.120 |
Why?
| | Clinical Medicine | 1 | 2014 | 20 | 0.110 |
Why?
| | Travel | 1 | 2015 | 123 | 0.110 |
Why?
| | Caregivers | 1 | 2021 | 826 | 0.110 |
Why?
| | Chickens | 2 | 2024 | 188 | 0.110 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 269 | 0.110 |
Why?
| | Clinical Laboratory Techniques | 1 | 2014 | 86 | 0.110 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2014 | 95 | 0.110 |
Why?
| | Cohort Studies | 3 | 2020 | 5431 | 0.110 |
Why?
| | Child, Hospitalized | 1 | 2013 | 49 | 0.100 |
Why?
| | Area Under Curve | 1 | 2013 | 292 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2013 | 318 | 0.100 |
Why?
| | Respiration | 1 | 2013 | 192 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2014 | 166 | 0.100 |
Why?
| | Risk Factors | 2 | 2017 | 9865 | 0.100 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 336 | 0.100 |
Why?
| | Psychometrics | 3 | 2021 | 688 | 0.100 |
Why?
| | Survival Analysis | 1 | 2015 | 1293 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 230 | 0.100 |
Why?
| | Reproducibility of Results | 4 | 2021 | 3069 | 0.100 |
Why?
| | Aged, 80 and over | 1 | 2023 | 7128 | 0.090 |
Why?
| | Workload | 1 | 2013 | 154 | 0.090 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2013 | 249 | 0.090 |
Why?
| | Odds Ratio | 1 | 2013 | 1027 | 0.090 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 227 | 0.090 |
Why?
| | Health Personnel | 2 | 2014 | 649 | 0.090 |
Why?
| | Temperature | 1 | 2013 | 636 | 0.090 |
Why?
| | Sepsis | 1 | 2016 | 565 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2017 | 1712 | 0.080 |
Why?
| | Heart Rate | 1 | 2013 | 813 | 0.080 |
Why?
| | Oxygen | 1 | 2013 | 919 | 0.080 |
Why?
| | Logistic Models | 1 | 2013 | 1980 | 0.070 |
Why?
| | Pneumonia | 1 | 2013 | 616 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1056 | 0.070 |
Why?
| | Communication | 1 | 2013 | 844 | 0.070 |
Why?
| | Animals | 4 | 2024 | 35076 | 0.070 |
Why?
| | Inflammation | 1 | 2017 | 2721 | 0.070 |
Why?
| | Algorithms | 1 | 2014 | 1638 | 0.070 |
Why?
| | Adult | 5 | 2024 | 35711 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2013 | 3369 | 0.060 |
Why?
| | Anaplasma | 1 | 2024 | 2 | 0.060 |
Why?
| | Ehrlichia | 1 | 2024 | 3 | 0.060 |
Why?
| | Rickettsia | 1 | 2024 | 9 | 0.060 |
Why?
| | Bartonella | 1 | 2024 | 7 | 0.060 |
Why?
| | Siphonaptera | 1 | 2024 | 14 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2012 | 906 | 0.060 |
Why?
| | Ticks | 1 | 2024 | 19 | 0.060 |
Why?
| | Quality Improvement | 1 | 2013 | 1111 | 0.060 |
Why?
| | Cats | 1 | 2024 | 211 | 0.060 |
Why?
| | Dog Diseases | 1 | 2024 | 52 | 0.060 |
Why?
| | South America | 1 | 2024 | 56 | 0.060 |
Why?
| | Mosquito Vectors | 1 | 2023 | 23 | 0.050 |
Why?
| | Dogs | 1 | 2024 | 377 | 0.050 |
Why?
| | Pregnancy | 3 | 2024 | 6301 | 0.050 |
Why?
| | Brain | 1 | 2015 | 2629 | 0.050 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 54 | 0.050 |
Why?
| | Swine | 1 | 2024 | 744 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 109 | 0.050 |
Why?
| | Anthropometry | 1 | 2022 | 206 | 0.050 |
Why?
| | Mammals | 1 | 2023 | 269 | 0.050 |
Why?
| | International Cooperation | 1 | 2022 | 174 | 0.050 |
Why?
| | Paraguay | 1 | 2020 | 2 | 0.040 |
Why?
| | Sri Lanka | 1 | 2020 | 7 | 0.040 |
Why?
| | Endemic Diseases | 1 | 2020 | 31 | 0.040 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 43 | 0.040 |
Why?
| | Translations | 1 | 2020 | 17 | 0.040 |
Why?
| | Regression Analysis | 1 | 2022 | 991 | 0.040 |
Why?
| | Child Language | 1 | 2019 | 25 | 0.040 |
Why?
| | Translating | 1 | 2019 | 38 | 0.040 |
Why?
| | Rural Health | 1 | 2019 | 70 | 0.040 |
Why?
| | Culturally Competent Care | 1 | 2019 | 56 | 0.040 |
Why?
| | Viral Load | 1 | 2020 | 452 | 0.040 |
Why?
| | United States | 1 | 2015 | 14110 | 0.040 |
Why?
| | Chromatography, Affinity | 1 | 2017 | 83 | 0.040 |
Why?
| | Epitope Mapping | 1 | 2017 | 58 | 0.040 |
Why?
| | Contact Tracing | 1 | 2017 | 20 | 0.040 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 62 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2017 | 334 | 0.030 |
Why?
| | Macrolides | 1 | 2017 | 63 | 0.030 |
Why?
| | Colorado | 2 | 2017 | 4471 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2017 | 351 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 154 | 0.030 |
Why?
| | Young Adult | 2 | 2024 | 12404 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2016 | 141 | 0.030 |
Why?
| | World Health Organization | 1 | 2014 | 106 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2060 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1538 | 0.030 |
Why?
| | Random Allocation | 1 | 2014 | 353 | 0.030 |
Why?
| | Urban Population | 1 | 2016 | 439 | 0.030 |
Why?
| | HIV | 1 | 2012 | 225 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1372 | 0.020 |
Why?
| | DNA, Viral | 1 | 2012 | 384 | 0.020 |
Why?
| | Inpatients | 1 | 2014 | 462 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1051 | 0.020 |
Why?
| | Middle Aged | 2 | 2017 | 31322 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 14675 | 0.010 |
Why?
|
|
Olson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|